Recombinant Antibodies

Question 1

Alemtuzumab target

Answer 1

CD52

Question 2

Alemtuzumab use (2)

Answer 2

CLL, MS

Question 3

Bevacizumab target

Answer 3

VEGF

Question 4

Bevacizumab use (3)

Answer 4

Colorectal cancer, renal cell carcinoma, Neovascular age-related macular degeneration

Question 5

Cetuximab target

Answer 5

EGFR

Question 6

Cetuximab use (2)

Answer 6

Stage IV colorectal cancer, head and neck cancer

Question 7

Rituximab target

Answer 7

CD20

Question 8

Rituximab use (4)

Answer 8

B-cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP

Question 9

What drugs increases risk of progressive multifocal leukoencephalopathy.

Answer 9

Rituximab and Natalizumab

Question 10

Trastuzumab target

Answer 10

HER2/neu

Question 11

Trastuzumab use

Answer 11

Breast cancer

Question 12

Adalimumab, certolizumab, infliximab target

Answer 12

Soluble TNF-α

Question 13

What drug is a decoy TNF-α receptor and not a monoclonal antibody

Answer 13

Etanercept

Question 14

Eculizumab target

Answer 14

Complement protein C5

Question 15

Eculizumab use

Answer 15

Paroxysmal nocturnal hemoglobinuria

Question 16

Natalizumab target

Answer 16

α4-integrin

Question 17

Abciximab target

Answer 17

Platelet glycoproteins IIb/IIIa

Question 18

Abciximab use

Answer 18

Antiplatelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention

Question 19

Denosumab target

Answer 19

RANKL

Question 20

Denosumab use

Answer 20

Osteoporosis; inhibits osteoclast maturation (mimics

osteoprotegerin)

Question 21

Omalizumab target

Answer 21

IgE

Question 22

Omalizumab use

Answer 22

Allergic asthma; prevents IgE binding to FcεRI

Question 23

Palivizumab target

Answer 23

RSV F protein

Question 24

Palivizumab use

Answer 24

RSV prophylaxis for high-risk infants